IP Library › Assignment 026605/0801
Patent Assignment
Reel/Frame 026605/0801

Security Agreement

Recorded: 2011-07-18 Received: 2011-07-18 Pages: 12
Assignors
Assignee
GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
200 WEST STREET, NEW YORK, NY, 10282, UNITED STATES
Covered Properties (46)
Dihydrotetrabenanzine for the Treatment of Anxiety
Application: 12/997,258 →
Ocular Strips
Application: 61/444,221 →
Cylindrical Ocular Inserts
Application: 61/444,213 →
Pharmaceutical Composition
Application: 12/864,453 →
Use of 3, 11B-Cis-Dihydrotetrabenazine in the Treatment of Multiple Sclerosis and Autoimmune Myelitis
Application: 12/740,786 →
Pharmaceutical Compositions
Application: 12/855,620 →
Bupropion Hydrobromide and Therapeutic Applications
Application: 12/740,223 →
Quick Dissolve Compositions and Tablets Based Thereon
Application: 12/730,339 →
Bupropion Hydrobromide and Therapeutic Applications
Application: 12/672,137 →
Bupropion Hydrobromide and Therapeutic Applications
Application: 12/620,720 →
Pharmaceutical Compounds
Application: 12/555,695 →
Pharmaceutical Compounds
Application: 12/555,720 →
Pharmaceutical Compounds
Application: 12/555,732 →
Pharmaceutical Compositions
Application: 12/540,144 →
Bupropion Hydrobromide Polymorphs
Application: 12/536,772 →
Modified Release Composition of at Least One Form of Venlafaxine
Application: 12/425,972 →
Modified Release Composition of at Least One Form of Venlafaxine
Application: 12/425,819 →
Pharmaceutical Compositions
Application: 12/360,673 →
Controlled Release Dosage Forms
Application: 12/328,828 →
3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses
Application: 11/997,591 →
3,11 B-Cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease
Application: 11/997,675 →
Use of 3,1IB-Cis-Dihydrotetrabenazine for the Treatment of Symptoms of Huntingtons Disease
Application: 11/995,436 →
Controlled Release Formulations Using Intelligent Polymers
Application: 12/186,853 →
Controlled Release Dosage Forms
Application: 12/169,852 →
Modified-Release Formulations of a Bupropion Salt
Application: 11/993,723 →
Bupropion Hydrobromide and Therapeutic Applications
Application: 11/930,644 →
Modified Release Formulations of at Least One Form of Tramadol
Application: 11/928,908 →
Bupropion Hydrobromide and Therapeutic Applications
Application: 11/834,848 →
Modified Release Formulations of a Bupropion Salt
Application: 11/774,109 →
Multiparticulate Osmotic Delivery System
Application: 11/768,764 →
Modified Release Formulations of a Bupropion Salt
Application: 11/766,213 →
Modified Release Formulations of a Bupropion Salt
Application: 11/766,251 →
Modified Release Formulations of a Bupropion Salt
Application: 11/766,239 →
Modified Release Formulations of a Bupropion Salt
Application: 11/762,840 →
Modified Release Formulations of a Bupropion Salt
Application: 11/762,820 →
Modified Release Formulations of a Bupropion Salt
Application: 11/762,343 →
Modified Release Formulations of a Bupropion Salt
Application: 11/759,413 →
Modified Release Formulations of a Bupropion Salt
Application: 11/755,946 →
Modified Release Formulations of a Bupropion Salt
Application: 11/751,785 →
Modified Release Formulations of a Bupropion Salt
Application: 11/751,768 →
Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them
Application: 10/597,803 →
Modified Release Formulations of a Bupropion Salt
Application: 11/475,252 →
Modified Release Tablet of Bupropion Hydrochloride
Application: 11/451,496 →
Modified Release Compositions of at Least One Form of Tramadol
Application: 10/933,479 →
Controlled Release Dosage Forms
Application: 10/370,109 →
Extended Release Metformin Hydrochloride Formulations
Application: 09/845,496 →